CHEManager – The EU Commission believes it is encouraging investment with its proposed legislation. Paradoxically, however, it is reducing existing innovation incentives for the development of new medicines. It is completely neglected that not only this legislation influences the attractiveness of the EU as an investment location for life sciences. Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance comments on the draft EU Pharma Regulation. Read more.